Skip to Content
Merck

Key Documents

View All Documentation

SFRVN

Sf-RVN® Insect Cell Line

Synonym(s):

Sf9 rhabdovirus-negative (Sf-RVN®) Insect Cell Line

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

UNSPSC Code:
41116105
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

description

Sf9 rhabdovirus-negative (Sf-RVN®) Insect Cell Line

solubility

DMSO: 10%

shipped in

liquid nitrogen

storage temp.

−196°C

General description

Sf-RVN® cells are provided to customers in vials containing 1 mL at 10 x 106 cells/mL. Cells are banked in EX-CELL® CD Insect Cell Medium and 10% DMSO.
The Sf-RVN® Insect Cell Line is a rhabdovirus-negative Sf9 cell line that can be grown in both adherent and suspension culture. Sf-RVN® Insect Cell Line has been adapted for growth in chemically defined medium to be used for the production of recombinant proteins, adeno-associated viruses (AAV) and viral-like particles (VLP). The cell line was tested for adventitious agents and banked under GMP conditions. A technical user guide, with detailed protocols for optimal performances, is provided with the cell line.The EX-CELL® CD Insect Cell Medium, recommended for use, is optimized to get excellent growth and productivity of the Sf-RVN® Insect Cell Line. Combined, these two products form the Sf-RVN® Platform.

Cell Line Origin

Sf-RVN® is an insect cell line originally derived from ovarian tissue of Spodoptera frugiperda (Sf) pupae. The parental line, IPLB-SF-21 (renamed IPLB-SF-21 AE after adaptation into TC-100 medium), was established by J. Vaughn at the Insect Pathology Beltsville in Maryland, USA in the late 1960s. A subclone, designated Sf9, was established in 1983 by G. Smith and C. Cherry. Sf-RVN® was isolated from Sf9 by GlycoBac, LLC.

Physical form

Sf-RVN® cells are provided to customers in vials containing 1 mL at 10 x 106cells/mL. Cells are banked in EX-CELL® CD Insect Cell Medium and 10% DMSO

Other Notes

Sf-RVN® is an insect cell line originally derived from ovarian tissue of Spodoptera frugiperda (Sf) pupae. The parental line, IPLB-SF-21 (renamed IPLB-SF-21 AE after adaptation into TC-100 medium), was established by J. Vaughn at the Insect Pathology Beltsville in Maryland, USA in the late 1960s. A subclone, designated Sf9, was established in 1983 by G. Smith and C. Cherry. Sf-RVN® was isolated from Sf9 by GlycoBac, LLC.

Legal Information

EX-CELL is a registered trademark of Merck KGaA, Darmstadt, Germany
Sf-RVN is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

12 - Non Combustible Liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Virus-like Particle (VLP) Vaccine Bioprocessing and Formulation Steps

This technical article breaks down the steps of upstream and downstream bioprocessing and formulation of virus-like particle vaccines.

Cell and Gene Therapy Manufacturing: Upstream Processing for AAV and Lentivirus Platforms

Minimize the complexities of cell and gene therapy production. Switch to upstream viral vector platforms to enhance scalability and simplify GMP manufacturing.

Bioprocessing And Scale-Up Of Suspension HEK293 Cells For AAV Manufacturing

To address scalability challenges of AAV manufacturing, we developed an HEK293 suspension cell line that can be used across many serotypes. Get the data in this article.

View All Articles

Related Content

病毒载体上游平台

针对病毒载体生产的转染解决方案采用悬浮细胞系、化学成分明确的培养基以及性能已得到证明的工艺。

Viral Vector Upstream Platforms

A transfection-based solution to viral vector production using a suspension cell line, chemically defined medium, and a process with proven performance at scale.